Vol 71, No 1 (2020)
Clinical vignette
Published online: 2019-09-30
Worsening of unrecognized tumour-induced osteomalacia with inadvertent use of recombinant human parathyroid hormone
1
, 1, 2, 1, 3, 1
, 1, 2, 1, 3, 1
Abstract
Not required for Clinical Vignette.
Keywords: tumour-induced osteomalaciateriparatidehypophosphataemiafragility fracture
References
- Liu S, Quarles LD. How fibroblast growth factor 23 works. J Am Soc Nephrol. 2007; 18(6): 1637–1647.
- Pal R, Bhadada SK, Shingare A, et al. Tumor-induced osteomalacia: experience from three tertiary care centres In India. Endocr Connect. 2019 [Epub ahead of print].
- Minisola S, Peacock M, Fukumoto S, et al. Tumour-induced osteomalacia. Nat Rev Dis Primers. 2017; 3: 17044.
- Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004; 19(3): 429–435.
- Blau JE, Collins MT. The PTH-Vitamin D-FGF23 axis. Rev Endocr Metab Disord. 2015; 16(2): 165–174.
- Lanske B, Razzaque MS. Molecular interactions of FGF23 and PTH in phosphate regulation. Kidney Int. 2014; 86(6): 1072–1074.
- Hajime M, Okada Y, Mori H, et al. A case of teriparatide-induced severe hypophosphatemia and hypercalcemia. J Bone Miner Metab. 2014; 32(5): 601–604.
